NIHR-supported trial tests a rapid, low-cost point-of-care test that can diagnose flu, COVID‑19, and RSV in minutes, potentially speeding up winter diagnosis and care across the NHS.
NICE has recommended dupilumab, a first-of-its-kind targeted COPD treatment that reduces flare-ups and improves lung function, offering new hope to thousands of patients.
Researchers in Edinburgh have developed a rapid stool-based test aiming to improve the diagnosis of inflammatory bowel disease and reduce the need for invasive procedures.
NICE recommends natalizumab, including a lower-cost biosimilar, as a new treatment for adults with highly active relapsing-remitting multiple sclerosis, expanding options for thousands of patients.
A new study suggests the shingles vaccine could reduce dementia risk and may even slow progression in those already diagnosed, offering hope for millions.
The UK-US pharma deal removes tariffs, boosts NHS access to innovative medicines, and drives significant life-sciences investment, safeguarding patients and industry growth.
GSK is investing £45 m with the Fleming Initiative to launch six “Grand Challenge” research programmes using cutting-edge AI to tackle antimicrobial resistance against pathogens like MRSA, Gram-negative bacteria, and fungi.
The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
NHS hospitals are piloting a rapid 15-minute blood test to distinguish viral vs bacterial infections in children, enabling faster diagnosis and treatment of serious illnesses like sepsis and meningitis.
Researchers at the University of Surrey are creating immune digital twins, virtual models of individual immune systems, to advance personalised medicine and deliver tailored treatments.